Met Life Investment Management, LLC Travere Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 41,143 shares of TVTX stock, worth $729,053. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,143
Previous 40,832 0.76%
Holding current value
$729,053
Previous $335,000 71.64%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$7.89 - $15.21 $2,453 - $4,730
311 Added 0.76%
41,143 $575,000
Q2 2024

Aug 13, 2024
BUY
$5.26 - $8.28 $41,254 - $64,940
7,843 Added 23.77%
40,832 $335,000
Q1 2024

May 14, 2024
BUY
$7.18 - $9.82 $236,861 - $323,951
32,989 New
32,989 $254,000
Q3 2023

May 09, 2024
BUY
$7.64 - $17.25 $45,312 - $102,309
5,931 Added 18.25%
38,438 $343,000
Q2 2023

Apr 29, 2024
BUY
$15.3 - $22.61 $588,101 - $869,083
38,438 New
38,438 $590,000
Q2 2023

Aug 10, 2023
BUY
$15.3 - $22.61 $90,744 - $134,099
5,931 Added 18.25%
38,438 $590,000
Q1 2023

May 09, 2024
BUY
$17.82 - $22.89 $579,274 - $744,085
32,507 New
32,507 $731 Million
Q2 2022

May 10, 2024
SELL
$20.94 - $30.01 $27,054 - $38,772
-1,292 Reduced 3.82%
32,507 $787,000
Q2 2022

Mar 22, 2023
SELL
$20.94 - $30.01 $27,054 - $38,772
-1,292 Reduced 3.82%
32,507 $787,000
Q2 2022

Aug 11, 2022
SELL
$20.94 - $30.01 $27,054 - $38,772
-1,292 Reduced 3.82%
32,507 $788,000
Q1 2022

May 10, 2024
BUY
$23.61 - $30.6 $797,994 - $1.03 Million
33,799 New
33,799 $871,000
Q1 2022

Jun 20, 2023
BUY
$23.61 - $30.6 $30,504 - $39,535
1,292 Added 3.97%
33,799 $871,000
Q1 2022

Mar 22, 2023
BUY
$23.61 - $30.6 $294,534 - $381,735
12,475 Added 58.5%
33,799 $871,000
Q1 2022

May 12, 2022
BUY
$23.61 - $30.6 $294,534 - $381,735
12,475 Added 58.5%
33,799 $871,000
Q4 2021

Jun 21, 2023
SELL
$24.34 - $31.17 $272,194 - $348,574
-11,183 Reduced 34.4%
21,324 $661,000
Q3 2021

Jun 21, 2023
SELL
$12.98 - $25.03 $145,155 - $279,910
-11,183 Reduced 34.4%
21,324 $517,000
Q2 2021

Jun 21, 2023
SELL
$14.11 - $26.4 $157,792 - $295,231
-11,183 Reduced 34.4%
21,324 $311,000
Q1 2021

May 17, 2024
SELL
$23.37 - $31.77 $272,611 - $370,597
-11,665 Reduced 35.36%
21,324 $532,000
Q1 2021

Jun 26, 2023
SELL
$23.37 - $31.77 $261,346 - $355,283
-11,183 Reduced 34.4%
21,324 $532 Million
Q1 2021

Mar 22, 2023
SELL
$23.37 - $31.77 $261,346 - $355,283
-11,183 Reduced 34.4%
21,324 $532,000
Q1 2021

May 14, 2021
BUY
$23.37 - $31.77 $498,341 - $677,463
21,324 New
21,324 $532,000

Others Institutions Holding TVTX

# of Institutions
192
Shares Held
84.5M
Call Options Held
776K
Put Options Held
900K
View Full List

About Travere Therapeutics, Inc.

TVTX Quotes by TradingView
  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.14B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email